摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-Ethoxy-1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)pyrazolo<3,4-d>pyrimidin-4(5H)-one | 111375-32-7

中文名称
——
中文别名
——
英文名称
3-Ethoxy-1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)pyrazolo<3,4-d>pyrimidin-4(5H)-one
英文别名
3-Ethoxy-1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidin-4(5H)-one;3-Ethoxy-1-[2,3,5-tri-O-benzoyl-beta-d-ribofuranosyl]pyrazolo[3,4-d]pyrimidin-4(5H)-one;[(2R,3R,4R,5R)-3,4-dibenzoyloxy-5-(3-ethoxy-4-oxo-5H-pyrazolo[3,4-d]pyrimidin-1-yl)oxolan-2-yl]methyl benzoate
3-Ethoxy-1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)pyrazolo<3,4-d>pyrimidin-4(5H)-one化学式
CAS
111375-32-7
化学式
C33H28N4O9
mdl
——
分子量
624.607
InChiKey
XKISAMAAUYACFE-NYBSAPDNSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.6
  • 重原子数:
    46
  • 可旋转键数:
    13
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.21
  • 拓扑面积:
    157
  • 氢给体数:
    1
  • 氢受体数:
    11

反应信息

  • 作为反应物:
    描述:
    3-Ethoxy-1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)pyrazolo<3,4-d>pyrimidin-4(5H)-onesodium methylate 作用下, 以 为溶剂, 以85%的产率得到3-Ethoxy-1-β-D-ribofuranosylpyrazolo<3,4-d>pyrimidin-4(5H)-one
    参考文献:
    名称:
    某些与腺苷,肌苷和鸟苷相关的3-烷氧基-1-β-D-呋喃呋喃糖基吡唑并[3,4- d ]嘧啶的合成†
    摘要:
    在结构上与腺苷,肌苷和鸟苷相关的几种3-烷氧基取代的吡唑并[3,4- d ]嘧啶核糖核苷已经通过预先形成的含有3-烷氧基取代基的糖苷配基前体的直接糖基化作用而制备。5(3)-氨基-3(5)-乙氧基吡唑-4-羧酰胺(6b)与甲酰胺或乙基黄原酸钾的闭环得到3-乙氧基铝嘌呤醇(7b)和3-乙氧基-6-thioxopyrazolo [3,4- d ]-嘧啶-4(5 H,7 H)-一(10)。10的甲基化得到相应的6-甲硫基衍生物15。5(3)-甲氧基吡唑-4-羧酰胺(6a)与甲酰胺一起得到3-甲氧基铝嘌呤醇(7a)。用乙酸甲form提供的4-氨基-3-甲氧基吡唑并[3,4- d ]嘧啶(4)处理5(3)-氨基-3(5)-甲氧基吡唑-4-腈(5a)。在三氟化硼醚化物的存在下,7b与1 - O-乙酰基-2,3,5-三-O-苯甲酰基-D-呋喃呋喃糖进行高温糖基化反应,得到N-1和N-2糖基的2:1混合物
    DOI:
    10.1002/jhet.5570230651
  • 作为产物:
    参考文献:
    名称:
    某些与腺苷,肌苷和鸟苷相关的3-烷氧基-1-β-D-呋喃呋喃糖基吡唑并[3,4- d ]嘧啶的合成†
    摘要:
    在结构上与腺苷,肌苷和鸟苷相关的几种3-烷氧基取代的吡唑并[3,4- d ]嘧啶核糖核苷已经通过预先形成的含有3-烷氧基取代基的糖苷配基前体的直接糖基化作用而制备。5(3)-氨基-3(5)-乙氧基吡唑-4-羧酰胺(6b)与甲酰胺或乙基黄原酸钾的闭环得到3-乙氧基铝嘌呤醇(7b)和3-乙氧基-6-thioxopyrazolo [3,4- d ]-嘧啶-4(5 H,7 H)-一(10)。10的甲基化得到相应的6-甲硫基衍生物15。5(3)-甲氧基吡唑-4-羧酰胺(6a)与甲酰胺一起得到3-甲氧基铝嘌呤醇(7a)。用乙酸甲form提供的4-氨基-3-甲氧基吡唑并[3,4- d ]嘧啶(4)处理5(3)-氨基-3(5)-甲氧基吡唑-4-腈(5a)。在三氟化硼醚化物的存在下,7b与1 - O-乙酰基-2,3,5-三-O-苯甲酰基-D-呋喃呋喃糖进行高温糖基化反应,得到N-1和N-2糖基的2:1混合物
    DOI:
    10.1002/jhet.5570230651
点击查看最新优质反应信息

文献信息

  • Synthesis of certain 3-alkoxy-1-β-D-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidines structurally related to adenosine, inosine and guanosine
    作者:Jack D. Anderson、N. Kent Dalley、Ganapathi R. Revankar、Roland K. Robins
    DOI:10.1002/jhet.5570230651
    日期:1986.11
    Several 3-alkoxysubstituted pyrazolo[3,4-d]pyrimidine ribonucleosides structurally related to adenosine, inosine and guanosine have been prepared by the direct glycosylation of preformed aglycon precursor containing a 3-alkoxy substituent. Ring closure of 5(3)-amino-3(5)-ethoxypyrazole-4-carboxamide (6b) with either formamide or potassium ethyl xanthate gave 3-ethoxyallopurinol (7b) and 3-ethoxy-6-thioxopyrazolo[3
    在结构上与腺苷,肌苷和鸟苷相关的几种3-烷氧基取代的吡唑并[3,4- d ]嘧啶核糖核苷已经通过预先形成的含有3-烷氧基取代基的糖苷配基前体的直接糖基化作用而制备。5(3)-氨基-3(5)-乙氧基吡唑-4-羧酰胺(6b)与甲酰胺或乙基黄原酸钾的闭环得到3-乙氧基铝嘌呤醇(7b)和3-乙氧基-6-thioxopyrazolo [3,4- d ]-嘧啶-4(5 H,7 H)-一(10)。10的甲基化得到相应的6-甲硫基衍生物15。5(3)-甲氧基吡唑-4-羧酰胺(6a)与甲酰胺一起得到3-甲氧基铝嘌呤醇(7a)。用乙酸甲form提供的4-氨基-3-甲氧基吡唑并[3,4- d ]嘧啶(4)处理5(3)-氨基-3(5)-甲氧基吡唑-4-腈(5a)。在三氟化硼醚化物的存在下,7b与1 - O-乙酰基-2,3,5-三-O-苯甲酰基-D-呋喃呋喃糖进行高温糖基化反应,得到N-1和N-2糖基的2:1混合物
查看更多

同类化合物

别嘌呤醇核糖苷 [3,4-二乙酰氧基-5-(5-甲硫基-2,4,8,9-四氮杂双环[4.3.0]壬-2,4,7,10-四烯-9-基)四氢呋喃-2-基]甲基乙酸酯 4-氨基-3-苄基-1H-吡唑并[3,4-d]嘧啶-1-β-D-呋喃核糖 1 beta-呋喃核糖基-4-(甲硫基)吡唑并(3,4-d)嘧啶 4-amino-3-bromo-6-methoxy-1-(β-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine 4-amino-3-bromo-5-methyl-1-(β-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine-6-one 8-aza-7-deaza-7-propynyladenosine 1-(β-D-ribofuranosyl)-4,6-bis(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine 1-(β-D-ribofuranosyl)-3-carboxy-4,6-dimethylmercaptopyrazolo<3,4-d>pyrimidine 4-amino-1-(α-D-arabinofuranosyl)pyrazolo<3,4-d>pyrimidine 2-(5-Amino-4-iminopyrazolo[3,4-d]pyrimidin-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol;hydrochloride 1-(β-D-ribofuranosyl)-3-thiocarbamoyl-4-amino-6-methylmercaptopyrazolo<3,4-d>pyrimidine 1-(β-D-ribofuranosyl)-4-amino-6-methylmercaptopyrazolo<3,4-d>pyrimidine-3-carboxamidine 1-(β-D-ribofuranosyl)-3-thiocarbamoyl-4,6-dimethylmercaptopyrazolo<3,4-d>pyrimidine 1-(β-D-ribofuranosyl)-3-cyano-4-(N-piperidino)-6-methylmercaptopyrazolo<3,4-d>pyrimidine 1-(β-D-ribofuranosyl)-3-cyano-4-(N-morpholino)-6-methylmercaptopyrazolo<3,4-d>pyrimidine methyl 1-(β-D-ribofuranosyl)-4,6-dimethylmercaptopyrazolo<3,4-d>pyrimidine-3-imidocarboxylate 1-(β-D-ribofuranosyl)-3-cyanomethyl-4-(N-morpholino)-6-methylmercaptopyrazolo<3,4-d>pyrimidine methyl 1-(β-D-ribofuranosyl)-4-methoxy-6-methylmercaptopyrazolo<3,4-d>pyrimidine-3-imidocarboxylate 1-(β-D-ribofuranosyl)-3-cyanomethyl-4-amino-6-methylmercaptopyrazolo<3,4-d>pyrimidine methyl 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl) tetrahydrofuran- 2-yl]-1H-pyrazolo[3,4-d]pyrimidine-3-carboximidoate 4-amino-1-(2,3,5-tri-O-benzyl-α-D-arabinofuranosyl)pyrazolo<3,4-d>pyrimidine 4-Amino-3-methoxy-1-β-D-ribofuranosylpyrazolo<3,4-d>pyrimidine 4-amino-1-β-D-ribofuranosylpyrazolo<3,4-d>pyrimidine-3-carbonitrile 4-amino-1-(β-D-ribofuranosyl)-3-[2-(methoxycarbonyl)ethenyl]-1H-pyrazolo[3,4-d]pyrimidine 1-Pentofuranosyl-1h-pyrazolo[3,4-d]pyrimidin-4-amine 4-Amino-1-pentofuranosyl-1h-pyrazolo[3,4-d]pyrimidine-3-carbonitrile 4-Amino-1-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrazolo[3,4-d]pyrimidine-3-carboximidamide Methyl 4-amino-1-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrazolo[3,4-d]pyrimidine-3-carboximidate 1H-Pyrazolo[3, 4-amino-1-beta-D-ribofuranosyl-, hydrazide, hemihydrate 2-(Hydroxymethyl)-5-[4-(methylamino)pyrazolo[3,4-d]pyrimidin-1-yl]oxolane-3,4-diol [3,4-Diacetyloxy-5-(4-chloropyrazolo[3,4-d]pyrimidin-1-yl)oxolan-2-yl]methyl acetate 1-beta-D-ribofuranosyl-4-methoxypyrazolo[3,4-d] pyrimidine 2-[4-(Dimethylamino)pyrazolo[3,4-d]pyrimidin-1-yl]-5-(hydroxymethyl)oxolane-3,4-diol 4-{[(4-Nitrophenyl)methyl]sulfanyl}-1-pentofuranosyl-1H-pyrazolo[3,4-d]pyrimidine 2-(4-Hydrazinylpyrazolo[3,4-d]pyrimidin-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol [5-[4-(Benzylamino)pyrazolo[3,4-d]pyrimidin-1-yl]-3,4-dihydroxyoxolan-2-yl]methyl acetate 2-(Hydroxymethyl)-5-(4-prop-2-enylsulfanylpyrazolo[3,4-d]pyrimidin-1-yl)oxolane-3,4-diol N-Benzyl-1-pentofuranosyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 2-(Hydroxymethyl)-5-pyrazolo[3,4-d]pyrimidin-1-yloxolane-3,4-diol [5-[4-(Furan-2-ylmethylamino)pyrazolo[3,4-d]pyrimidin-1-yl]-3,4-dihydroxyoxolan-2-yl]methyl acetate [3,4-Diacetyloxy-5-(4-anilinopyrazolo[3,4-d]pyrimidin-1-yl)oxolan-2-yl]methyl acetate 1-Pentofuranosyl-N-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine [3,4-Diacetyloxy-5-[4-(3-methyl-5-nitroimidazol-4-yl)sulfanylpyrazolo[3,4-d]pyrimidin-1-yl]oxolan-2-yl]methyl acetate 2-[4-(Furan-2-ylmethylamino)pyrazolo[3,4-d]pyrimidin-1-yl]-5-(hydroxymethyl)oxolane-3,4-diol 2-[4-(Hydroxyamino)pyrazolo[3,4-d]pyrimidin-1-yl]-5-(hydroxymethyl)oxolane-3,4-diol 2-(Hydroxymethyl)-5-[4-(3-methyl-5-nitroimidazol-4-yl)sulfanylpyrazolo[3,4-d]pyrimidin-1-yl]oxolane-3,4-diol [3,4-Diacetyloxy-5-[4-(aziridin-1-yl)pyrazolo[3,4-d]pyrimidin-1-yl]oxolan-2-yl]methyl acetate 1-(β-D-ribofuranosyl)-4,6-bis(chlorodifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine 1-(β-D-ribofuranosyl)-4,6-bis(difluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine